What is the most recent earnings date for CLSD stock?
CLEARSIDE BIOMEDICAL INC (CLSD) last reported earnings on 11/14/2025.
CLEARSIDE BIOMEDICAL INC (CLSD) Earnings History & Surprises
NASDAQ:CLSD • US1850632035
Current stock price
0.41 USD
-0.15 (-26.96%)
At close:
0.3516 USD
-0.06 (-14.24%)
After Hours:
CLSD Earnings overview
Past quarterly earnings results for CLEARSIDE BIOMEDICAL INC (CLSD), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.61
- Revenue Estimate
- 204K
Last Reported
Most Recent- Release Date
- Nov 14, 2025
- Period
- Q3 / 2025
- EPS Reported
- -$1.14
- EPS Surprise
- -112.89%
- Revenue Surprise
- -14.32%
Beat Rate
Last 8 Quarters 75%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -1.14 | -0.54 | -112.89% | 24.00% | 201K | 234.6K | -14.32% | -80.64% |
| Q2 2025 | -0.90 | -1.55 | 41.76% | 40.00% | 492K | 173.4K | 183.74% | 446.67% |
| Q1 2025 | -1.65 | -1.66 | 0.67% | 26.67% | 2.33M | 173.4K | 1,243.71% | 913.04% |
| Q4 2024 | -1.50 | -1.49 | -0.93% | -25.00% | 306K | 180.203K | 69.81% | -95.18% |
| Q3 2024 | -1.50 | -1.90 | 21.12% | 33.33% | 1.038M | 125.317K | 728.30% | 20.84% |
| Q2 2024 | -1.50 | -2.07 | 27.38% | 33.33% | 90K | 129.203K | -30.34% | -91.16% |
| Q1 2024 | -2.25 | -2.11 | -6.87% | - | 230K | 596.7K | -61.45% | 5,650.00% |
| Q4 2023 | -1.20 | -1.34 | 10.36% | 50.00% | 6.345M | 4.522M | 40.31% | 1,822.73% |
| Q3 2023 | -2.25 | -2.37 | 5.12% | -15.38% | 859K | 163.373K | 425.79% | 218.15% |
| Q2 2023 | -2.25 | -2.17 | -3.80% | -15.38% | 1.018M | 126.684K | 703.57% | 167.89% |
| Q1 2023 | -2.25 | -2.14 | -5.04% | -15.38% | 4K | 146.88K | -97.28% | -98.86% |
| Q4 2022 | -2.40 | -1.93 | -24.49% | -151.61% | 330K | 97.92K | 237.01% | -98.72% |
| Q3 2022 | -1.95 | -0.52 | -274.86% | -62.50% | 270K | 6.648M | -95.94% | -91.21% |
| Q2 2022 | -1.95 | -2.02 | 3.45% | -18.18% | 380K | 382.5K | -0.65% | -51.28% |
| Q1 2022 | -1.95 | -1.25 | -55.43% | - | 350K | 2.933M | -88.07% | 1,066.67% |
| Q4 2021 | 4.65 | 2.42 | 91.95% | 321.43% | 25.69M | 18.127M | 41.72% | 256,800.00% |
| Q3 2021 | -1.20 | -1.30 | 7.73% | -60.00% | 3.07M | 2.629M | 16.77% | -10.50% |
| Q2 2021 | -1.65 | -1.96 | 15.96% | 15.38% | 780K | 589.733K | 32.26% | 122.86% |
| Q1 2021 | -1.95 | -1.50 | -30.05% | -85.71% | 30K | 2.165M | -98.61% | -99.27% |
| Q4 2020 | -2.10 | -1.74 | -20.40% | - | 10K | 1.316M | -99.24% | - |
| Q3 2020 | -0.75 | -1.79 | 57.98% | - | 3.43M | 1.548M | 121.58% | - |
| Q2 2020 | -1.95 | -1.81 | -7.49% | - | 350K | 1.359M | -74.25% | - |
| Q1 2020 | -1.05 | -1.74 | 39.80% | - | 4.1M | 2.04M | 100.98% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
15.66%
Max EPS beat (4)
41.76%
Min EPS beat (4)
-0.93%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
556.39%
Max Revenue beat (4)
1,243.71%
Min Revenue beat (4)
69.81%
Analysis
In the last 4 quarters, CLSD has beaten EPS estimates in 3 out of 4 releases
CLSD has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, CLSD has beaten the EPS estimates by 15.7% on average.
In the last 4 quarters, CLSD has beaten the revenue estimates by 556.4% on average.
Related analysis
CLEARSIDE BIOMEDICAL INC / CLSD Earnings FAQ
Did CLEARSIDE BIOMEDICAL INC (CLSD) beat earnings estimates last quarter?
CLEARSIDE BIOMEDICAL INC (CLSD) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often CLEARSIDE BIOMEDICAL INC beats earnings estimates?
In the last 4 quarters, CLEARSIDE BIOMEDICAL INC (CLSD) has beaten EPS estimates in 3 out of 4 releases.